2014

Psychemedics Corporation Announces Third Quarter Profits EARNINGS UP 35% FROM Q3 2010

ACTON, Mass., Nov. 3, 2011 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2011.  The Company also announced a quarterly dividend of $0.12 per share payable to shareholders of record as of November 17, 2011 to be paid on December 1, 2011.  This will be the Company's 61st consecutive quarterly dividend.

The Company's revenue for the quarter ended September 30, 2011 was $6.3 million versus $5.1 million for the quarter ended September 30, 2010, an increase of 24%.  Net income for the quarter ended September 30, 2011 was $1.1 million or $0.21 per diluted share, versus $817 thousand or $0.16 per diluted share, for the comparable period last year, an increase of 35%. The Company's revenue for the nine months ended September 30, 2011 was $18.5 million, as compared to $15.0 million for the comparable period of 2010, an increase of 24%. Net income for the nine months ended September 30, 2011 was $3.1 million or $0.58 per diluted share, as compared to last year during which the Company earned $2.2 million or $0.42 per diluted share, an increase of 39%.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"Our third quarter results were strong, both on the top line as well as earnings.  The majority of our growth came from new business. However, in light of the current tepid economic environment, we were also encouraged to see growth in our base business.  We continued to have robust margins including a 29% pre-tax margin. While we maintained tight cost control, we also continue to make investments in sales and marketing. 

"Our balance sheet remained strong with no long-term debt and cash of $3.5 million.  There was a temporary increase in accounts receivable and corresponding reduction of cash from prior quarters due to a delay in August invoicing as a result of a one-time upgrade to our billing system. 

"Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward.     

"Therefore, the Board has declared a $0.12 dividend for the quarter. This is our 61st consecutive quarterly dividend. In addition, we continue to have a share buyback program in place."

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services.  Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: Neil Lerner

Vice President of Finance

(978) 206-8220

Neill@psychemedics.com  

 

PSYCHEMEDICS CORPORATION
STATEMENTS OF INCOME
(UNAUDITED)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2011

 

2010

 

 

2011

 

2010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

$6,315,142

 

$5,106,262

 

 

$18,542,666

 

$14,992,625

 

 

Cost of revenues

2,371,255

 

2,080,214

 

 

7,243,474

 

6,033,093

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

3,943,887

 

3,026,048

 

 

11,299,192

 

8,959,532

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

   General & administrative

1,018,967

 

850,312

 

 

2,898,426

 

2,760,195

 

 

   Marketing & selling

981,197

 

722,815

 

 

2,945,492

 

2,098,192

 

 

   Research & development

136,281

 

116,534

 

 

399,785

 

364,445

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

2,136,445

 

1,689,661

 

 

6,243,703

 

5,222,832

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

1,807,442

 

1,336,387

 

 

5,055,489

 

3,736,700

 

 

Interest income

773

 

4,940

 

 

4,790

 

19,422

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income before provision for income taxes

1,808,215

 

1,341,327

 

 

5,060,279

 

3,756,122

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

708,830

 

523,959

 

 

2,009,184

 

1,559,391

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

$1,099,385

 

$817,368

 

 

$3,051,095

 

$2,196,731

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

$0.21

 

$0.16

 

 

$0.58

 

$0.42

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income per share

$0.21

 

$0.16

 

 

$0.58

 

$0.42

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividends declared per share

$0.12

 

$0.12

 

 

$0.36

 

$0.36

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic

5,237,603

 

5,212,835

 

 

5,227,699

 

5,205,480

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, diluted

5,240,895

 

5,228,378

 

 

5,234,577

 

5,219,760

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

PSYCHEMEDICS CORPORATION
BALANCE SHEETS
(UNAUDITED)

 

 

 

 

September 30,

 

December 31,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 Current Assets:

 

 

 

 

 

   Cash and cash equivalents

$3,501,525

 

$3,720,488

 

 

   Short-term investments

--

 

2,018,452

 

 

   Accounts receivable, net of allowance for doubtful accounts

6,197,433

 

3,905,821

 

 

       of $138,067 in 2011 and $119,295 in 2010

 

 

 

 

 

   Prepaid expenses and other current assets

836,069

 

700,822

 

 

   Deferred tax assets  

362,153

 

239,831

 

 

 

 

 

 

 

 

Total Current Assets

10,897,180

 

10,585,414

 

 

 

 

 

 

 

 

Fixed Assets:

 

 

 

 

 

   Equipment & leasehold improvements

12,643,486

 

11,730,866

 

 

   Less accumulated depreciation

(10,917,452)

 

(10,663,996)

 

 

 

 

 

 

 

 

Net Fixed Assets

1,726,034

 

1,066,870

 

 

 

 

 

 

 

 

Other Assets

222,724

 

114,037

 

 

 

 

 

 

 

 

Total Assets

$  12,845,938

 

$ 11,766,321

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

   Accounts payable

$293,930

 

$699,833

 

 

   Accrued expenses

1,440,986

 

1,302,370

 

 

   Deferred revenue

--

 

16,605

 

 

 

 

 

 

 

 

Total Current Liabilities

1,734,916

 

2,018,808

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Equity:

 

 

 

 

 

   Preferred-stock, $0.005 par value, 872,521 shares authorized,

 

 

 

 

 

        no shares issued or outstanding

--

 

--

 

 

   Common stock, $0.005 par value; 50,000,000 shares authorized

 

 

 

 

 

       5,903,552 shares issued in 2011 and 5,877,358 shares issued 2010 

29,518

 

29,387

 

 

   Paid-in capital

27,982,277

 

27,764,992

 

 

   Accumulated deficit

(6,818,984)

 

(7,987,468)

 

 

   Less - Treasury stock at cost, 668,130 shares in 2011 and 665,345 in 2010

(10,081,789)

 

(10,059,398)

 

 

 

 

 

 

 

 

Total Shareholders' Equity

11,111,022

 

9,747,513

 

 

 

 

 

 

 

 

Total Liabilities and Shareholders' Equity

$12,845,938

 

$11,766,321

 

 

 

 

 

 

 

 

SOURCE Psychemedics Corporation



RELATED LINKS
http://www.psychemedics.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.